Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Chugai Pharmaceutical.

    Client Virtual Booth

    CHUGAI PHARMACEUTICAL

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Chugai Pharmaceutical
    japan Flag
    Country
    Country
    Japan
    Address
    Address
    1-1 Nihonbashi-Muromachi 2-Chome Chuo-ku, Tokyo 103-8324
    Telephone
    Telephone
    81-(0)3-3281-6611
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.chugai-pharm.co.jp/english/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Positive Phase III Results Showed Vabysmo Improved Vision for the First Time in Japanese in Angioid Streaks

    Details:

    Vabysmo (faricimab) is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor, which is being evaluated for the treatment of angioid streaks associated with neovascularization.


    Lead Product(s): Faricimab

    Therapeutic Area: Ophthalmology Product Name: Vabysmo

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 15, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for the AKT Inhibitor, Capivasertib for Advanc...

    Details:

    Truqap (capivasertib) is a first-in-class, potent, adenosine triphosphate (ATP)-competitive inhibitor of all three AKT isoforms (AKT1/2/3), is approved in combination with Faslodex (fulvestrant) for the treatment of advanced HER2-/HR+ breast cancer.


    Lead Product(s): Capivasertib,Fulvestrant

    Therapeutic Area: Oncology Product Name: Truqap

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: AstraZeneca

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 27, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials

    Details:

    Mitchga (nemolizumab) is an anti-IL-31 receptor A humanized monoclonal antibody, which is approved for the treatment of atopic dermatitis and prurigo nodularis.


    Lead Product(s): Nemolizumab

    Therapeutic Area: Dermatology Product Name: Mitchga

    Highest Development Status: ApprovedProduct Type: Large molecule

    Recipient: Maruho

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 26, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Chugai Obtains Regulatory Approval for “Piasky 340mg” for Paroxysmal Nocturnal Hemoglobinuria in Japan

    Details:

    Piasky (crovalimab) is a humanized complement inhibitor C5 monoclonal antibody. It is being developed for the treatment of adults and adolescents (12 years of age and above) with Paroxysmal Nocturnal Hemoglobinuria.


    Lead Product(s): Crovalimab

    Therapeutic Area: Rare Diseases and Disorders Product Name: Piasky

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 26, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Chugai Obtains Regulatory Approval for Vabysmo, the Only Bispecific Antibody in the Ophthalmology Field, for Additional Indication of Macular Edema Asso...

    Details:

    Vabysmo (faricimab) is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of macular edema associated with retinal vein occlusion.


    Lead Product(s): Faricimab

    Therapeutic Area: Ophthalmology Product Name: Vabysmo

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 26, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Results of Phase III Study of Enspryng in Patients with Generalized Myasthenia Gravis

    Details:

    Enspryng (satralizumab-mwge) is an IL-6 receptor antagonist, currently being evaluated in the phase III clinical trial studies with patients for the treatment of Generalized Myasthenia Gravis.


    Lead Product(s): Satralizumab

    Therapeutic Area: Immunology Product Name: Enspryng

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 21, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Chugai Files New Drug Application in Japan for Mosunetuzumab for Relapsed or Refractory Follicular Lymphoma

    Details:

    Lunsumio (mosunetuzumab) is a CD20xCD3 T cell-engaging bispecific antibody designed to target CD20 on B cells and CD3 on T cells. It is being evaluated for the treatment of relapsed and refractory follicular lymphoma.


    Lead Product(s): Mosunetuzumab

    Therapeutic Area: Oncology Product Name: Lunsumio

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 14, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Chugai Files for Additional Indication of Tecentriq for the Treatment of Alveolar Soft Part Sarcoma, an Ultra-rare Disease

    Details:

    Tecentriq (atezolizumab) is a USFDA approved programmed death-ligand 1 (PD-L1) blocking antibody. It is being evaluated for the treatment of alveolar soft part sarcoma, an ultra-rare disease.


    Lead Product(s): Atezolizumab

    Therapeutic Area: Oncology Product Name: Tecentriq

    Highest Development Status: Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 14, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for RET Receptor Tyrosine Kinase Inhibitor, Se...

    Details:

    Retevmo (selpercatinib) is an oral RET receptor tyrosine kinase inhibitor, small molecule drug candidate which is indicated for the treatment of RET fusion-positive solid tumors.


    Lead Product(s): Selpercatinib

    Therapeutic Area: Oncology Product Name: Retevmo

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 29, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Chugai Files for Additional Indication of Evrysdi for Pre-Symptomatic Spinal Muscular Atrophy and Additional Dosage for Infants up to 2 Months of Age

    Details:

    Evrysdi (risdiplam) is a survival of motor neuron 2 (SMN2) splicing modifier, which is being evaluated for the treatment of infants with pre-symptomatic spinal muscular atrophy.


    Lead Product(s): Risdiplam

    Therapeutic Area: Genetic Disease Product Name: Evrysdi

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 15, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search